The Future of Addiction Treatment Starts Here: GLP-1s Explained With Dr. Ken Spielvogel

On this episode of We’re Out Of Time, host Richard Taite sits down with Dr. Ken Spielvogel, Senior Medical Officer at Carrera Treatment Wellness & Spa, to explore one of the most talked-about breakthroughs in addiction medicine: GLP-1 medications. Originally developed for diabetes and weight loss, emerging research now suggests GLP-1s may significantly reduce cravings, compulsive behavior, and relapse risk in people struggling with substance use disorders.

Dr. Spielvogel explains how GLP-1 medications are being used in addiction treatment, including why injectable options outperform oral medications when it comes to compliance and effectiveness. The conversation breaks down how GLP-1s impact dopamine signaling in the brain, why they can decrease urges to use drugs or alcohol, and how their effects differ in individuals with substance use disorders. Richard and Dr. Spielvogel also discuss nicotine replacement therapy, brain fog, and the broader public health reality that over 50% of Americans are obese.

As the episode continues, Richard Taite makes a bold statement, calling GLP-1s “the best drug I’ve ever seen for the treatment of drug addiction and alcoholism.” Dr. Spielvogel expands on why the medication may be a game-changer, outlines the four leading causes of death these drugs may help reduce, and addresses side effects associated with rapid weight loss. The discussion emphasizes that medication alone is not enough without self-work, exercise, and lifestyle change. The episode concludes with a look at falling prices, expanded access, and the future of GLP-1s as preventative medicine.